Trials / Completed
CompletedNCT02937077
Atrial Fibrillation in Cryptogenic Stroke and TIA
The Nordic Atrial Fibrillation and Stroke Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 259 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Background: Different studies with real-life data and randomized controlled trials have shown a detection rate of paroxysmal atrial fibrillation (AF) of 10-20% in patients with cryptogenic stroke using insertable continuous cardiac monitoring for 6 months. More studies are needed, however, to identify factors which can be used to select the patients where the possibility of detecting AF with prolonged rhythm monitoring is highest, to evaluate the best duration of rhythm monitoring, to determine the optimal definition of short-term AF that warrants intervention and to evaluate whether intervention results in improved clinical outcomes. Methods: The NOR-FIB study is a multi-centre prospective observational trial, designed to evaluate detection of AF in cryptogenic stroke and transient ischemic attack (TIA). Patients admitted with cryptogenic stroke or TIA in stroke units in the Nordic countries, aged 18-80 years are included and have the Reveal LINQ® Insertable cardiac monitor system implanted for 12 months for the purpose of AF detection. Biomarkers that may identify patients, who could derive the most clinical benefit from the detection of AF by prolonged monitoring, are being studied. Conclusion: This NOR-FIB study will increase our knowledge regarding the occurrence of AF in patients with cryptogenic stroke and TIA that potentially can improve secondary prevention. The study will provide information on biomarkers that may be used to select cryptogenic TIA and stroke patients for long-term monitoring as well as information on the significance of short-term AF and optimal duration of cardiac rhythm monitoring.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Medtronic Reveal LINQ |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2021-10-01
- Completion
- 2021-10-01
- First posted
- 2016-10-18
- Last updated
- 2022-01-25
Locations
2 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT02937077. Inclusion in this directory is not an endorsement.